Industry Vet James Hartman Named CEO at of Ourself
James Hartman is the new Chief Executive Officer of Ourself, a biotech skincare company.
Prior to joining Ourself, Mr. Hartman served as Chief Commercial Officer at Alastin Skincare. He also held leadership positions at Obagi, Merz Aesthetics and Allergan Aesthetics. Most recently, Mr. Hartman served as President of Hugel Aesthetics where he oversaw the consecutive approval and commercialization of their neurotoxin across the US, Canada, and Australia.
“I am thrilled and honored to build upon Ourself’s robust scientific foundation as we expand and drive growth within the market. Our patented delivery system promises to revolutionize the skincare industry, breaking free from decades-old technological limitations,” says Mr. Hartman in a news release. “I am excited to collaborate with aesthetic clinicians nationwide to bring this cutting-edge skincare technology to their practice and patients.”
DermTech Files Chapter 11
DermTech, Inc. filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware.
The chapter 11 filing is a continuation of the Company’s strategic alternatives review process. Currently, the Company intends to continue its laboratory operations and processing orders for the DermTech Melanoma Test (DMT), while simultaneously conducting a process to sell substantially all of its assets.
Through the bankruptcy process, the Company intends to safeguard the interest of stakeholders and maximize the value of its assets.
Alongside the chapter 11 filings, the Company also implemented a reduction in force (RIF) to significantly reduce expenses associated with its current operations to preserve cash. This RIF resulted in an immediate workforce reduction of approximately 15 employees (approximately 20% of the Company’s workforce), with potential additional reductions of DermTech’s workforce in the future.
First Participants Dosed in Phase 1a Trial of VYN202, a Novel BD2-Selective BET Inhibitor
The first healthy volunteers have been dosed in the Phase 1a trial of VYNE Therapeutics Inc.’s VYN202, an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immuno-inflammatory diseases.
Top-line data are expected in the second half of 2024.
The Phase 1a trial is a first-in-human double-blind, placebo-controlled study in healthy volunteers and consists of single ascending dose (SAD) and multiple ascending dose (MAD) components. The trial is currently expected to enroll approximately 64 healthy adult subjects into five SAD and three MAD cohorts to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202.
Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Uppsala, Sweden-based Center of Excellence
The Swedish Medical Products Agency has issued a license update authorizing the future manufacture and bioanalytical testing of Galderma’s proprietary investigational ready-to-use liquid botulinum toxin A, RelabotulinumtoxinA.
The license updates, issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA.
